Insight Molecular Diagnostics Inc. Common Stock (IMDX) — Analysis Summary
Insight Molecular Diagnostics Inc. Common Stock (IMDX) has a market cap of $200.52M with year-over-year revenue growth of +115.6%. Net margin stands at -1238.5%. The stock trades at a P/E ratio of -4.2.
Key Takeaways
- Revenue changed +115.6% year-over-year
- Net margin of -1238.5%
- P/E ratio of -4.2
Compared to other companies in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector, IMDX posted revenue growth of +115.6% and trades at a P/E of -4.2.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.